1. Introduction {#sec1}
===============

Optic neuritis (ON) is the most common inflammatory demyelinating neuropathy \[[@B1]\]. It can manifest as either an isolated episode or be caused as a result of the patient suffering from multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) \[[@B2], [@B3]\].

The optic neuritis treatment trial (ONTT) studied patients between 18 and 45 years old with acute, unilateral optic neuritis; most of whom had good vision recovery \[[@B4]\]. This has been classified as typical ON \[[@B5]\]. In ON patients, ethnicity has been documented as an important factor influencing clinical features and the outcome \[[@B6]\]. It has been identified that NMOSD is more likely to develop in Asia, whereas MS is more prevalent in western countries \[[@B7]\]. Previously, we reported a cohort of Chinese ON patients with atypical clinical features and poor recovery \[[@B8]\]. African-American patients were also found to have more severe vision loss and less vision recovery \[[@B9]\].

Although, the ONTT is the largest study to date of ON; it included only patients between 18 and 45 years. There are, currently, only a limited number of studies on the clinical features of ON in the older population. We previously reported a cohort of Chinese ON patients of all ages \[[@B10]\]. We observed less vision recovery in patients older than 45 years, compared to patients younger than 45 years. However, we could not divide patients into more specific age groups for analysis due to the small number of patients. We therefore carried out this study to describe the clinical manifestations and investigative outcomes in two age groups, middle-aged patients (45--65 years) and elderly patients (\>65 years).

2. Patients and Methods {#sec2}
=======================

This retrospective study included patients evaluated for a first episode of optic neuritis in the Neuro-ophthalmology Clinic of the Chinese PLA General Hospital (PLAGH) in Beijing between May 2008 and November 2012. Only patients who had a first episode of ON were included in the study. To compare clinical features, we divided patients into two groups, middle-aged group (45--65 years) and elderly group (older than 65 years).

Inclusion criteria are the following: (i) the first episode ON with BCVA loss; (ii) older than 45 years; (iii) follow-up of ≥5 years; (iv) no prior steroid treatment; (v) objective evidence of visual abnormalities: relative afferent papillary defect (RAPD), visual field defects, and abnormal visual evoke potential (VEP).

Exclusion criteria are the following: (i) nonarteritic anterior ischemic optic neuropathy (NAION), (ii) disorders other than ON, including compressive, hereditary, vascular, toxic, traumatic, metabolic, or infiltrative neuropathy, (iii) ocular comorbidity including uveitis or glaucoma, and (iv) amblyopia.

To exclude a diagnosis of NAION, known risk factors for ischemic disease were evaluated, including \[[@B11]\] (i) systematic conditions: hypertension, diabetes, hyperlipidaemia, sleep apnoea syndrome, and nocturnal hypotension; (ii) medical history: erectile dysfunction drugs, amiodarone, and cataract surgery; (iii) "crowded" optic disc.

The protocol of the study was approved by the institutional review board at the Chinese PLAGH and performed in accordance with the tenets of the Helsinki Declaration. Informed consent was obtained from all the patients.

2.1. Clinical, Immunological, and Radiological Assessment {#sec2.1}
---------------------------------------------------------

All patients underwent the ophthalmic exam, including ocular symptoms, best corrected visual acuity (BCVA), pupil function test, optic disc appearance, colour vision test, optical coherence tomography (OCT), and fluorescence angiography (FFA). The BCVA in all patients was evaluated using the Snellen visual chart, and the data was transformed as the logarithm of the minimum angle of resolution (logMAR) values \[[@B12]\]. In patients with bilateral optic neuritis, only the eyes presenting the worst BCVA at onset were included in this study.

Because of the retrospective nature of the study, some investigation results were unavailable for a number of patients. Orbital magnetic resonance imaging (MRI) and head MRI were used to detect the Gd-enhancement in the optic nerve or in any brain lesion. The MR images were reviewed by the same experienced radiologist to ensure consistency of the results. Serums were screened for antinuclear antibody (ANA), antineutrophil cytoplasmic antibodies (ANCA), extractable nuclear antigen antibodies (SSA and SSB), anticardiolipin antibodies (ACLs and *β*2-GPI), rheumatoid factor (RF) and major histocompatibility complex-B27 (HLA-B27), and aquaporin-4 antibody (AQP4-Ab) status. The serum AQP4-Ab level was assessed using the cell-based assay \[[@B13]\].

2.2. Statistical Analyses {#sec2.2}
-------------------------

All statistical analyses were performed using SPSS 22.0 software (IBM Corporation, New York, USA). Chi-squared Pearson test was applied for categorical variables and Mann--Whitney *U* test for quantitative variables. The Pearson correlation test was also used to determine the relationships between the recovery indices. A value of *p* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Demographic and Clinical Characteristics {#sec3.1}
---------------------------------------------

76 patients (99 eyes) were included in this study, of which 44 were females (57.9%). The mean age at onset was 55.5 ± 8.3 (range: 45--83) years. The follow-up duration ranged from 5--8 years, with a mean of 5 ± 1.49 years. There were 53 (69.7%) patients with unilateral disease and 23 (30.3%) with bilateral disease. The average relapse rate was 0.46 ± 0.23/year (range: 0.14--1/year). The details of the demographic and clinical characteristics of middle-aged and older patients are summarized in [Table 1](#tab1){ref-type="table"}. All patients received intravenous methylprednisolone therapy (1 g/day) for three days, followed by oral prednisolone (1 mg/kg/day) for two weeks, in keeping with the recommendations of the ONTT \[[@B4]\].

3.2. Visual Acuity {#sec3.2}
------------------

Vision loss was severe at onset, with BCVA \< 20/400 in 74 (74.8%) eyes. 49 (72.06%) patients aged ≤ 65 years and 8 (100%) patients aged ≥ 65 years had BCVA \< 20/400. At the last follow-up, 30 (44.12%) patients aged ≤ 65 years and 7 (87.5%) patients aged ≥ 65 years had BCVA \< 20/400. The initial BCVA of the patients aged \< 65 years was significantly better from that of the patients aged ≥ 65 years (*p* = 0.006); however, there was no difference in final BCVA (*p* = 0.740). There was also no significant difference between initial BCVA and final BCVA in patients \< 65 or ≥65 years (*p* = 0.076, *p* = 0.200). The detailed comparison is summarized in [Table 2](#tab2){ref-type="table"}.

3.3. Immunological Findings {#sec3.3}
---------------------------

Of the 76 patients, 49 patients had AQP4-Ab test, of which 11 (22.4%) were seropositive and 38 (77.6%) were seronegative. 64 patients had autoimmune antibody screening test, and 21 (21.6%) were abnormal, including antinuclear antibody (ANA), anticardiolipin antibody (ACA), double-stranded DNA (dsDNA), anti-Ro antibody (SS-A), anti-La antibody (SS-B), anti-*β*-glycoprotein antibody, rheumatoid factor (RF), and HLA-B27. The positive rate was not related to AQP4-Ab rate. There was no significant difference between patients \< 65 years and ≥65 years.

3.4. MR Imaging Findings {#sec3.4}
------------------------

Of the 76 patients, 53 patients had orbital MRI at presentation, of which 44 (83.0%) had optic nerve T2 lesions or optic nerve enhancement. 50 patients had head MRI imaging at the onset, 5 (10%) had demyelinating lesions, 8 (16%) had T2 lesions, and 9 (18%) had ischemic foci. The abnormal to normal ratio was not significantly different between patients \< 65 years and ≥65 years.

3.5. OCT Imaging Findings {#sec3.5}
-------------------------

Of the 76 patients, OCT was performed in 51 patients, with the average time from the onset being 22.75 ± 23.00 months. Of the 51 patients, 45 patients were \<65 years and 6 were ≥65 years. The peripapillary retinal nerve fibre layer (pRNFL) thickness (*μ*m) was measured at the final follow-up. The thickness of pRNFL was not significantly different between patients \< 65 years and ≥65 years, but the temporal thickness was significantly reduced in those with BCVA \< 20/400 compared to ≥20/400 (*p* \< 0.05) ([Figure 1](#fig1){ref-type="fig"}). Thinning of the pRNFL was also found in those with positive AQP4-Ab (*p* = 0.022).

3.6. Correlation of Final BCVA with Other Parameters {#sec3.6}
----------------------------------------------------

The final BCVA was found to be significantly correlated only with the initial BCVA and temporal RNFL thickness (*p* = 0.001, *p* = 0.045). Other variables examined in this patient cohort, such as sex, age, laterality, initial disc appearance, systemic association, orbital MRI findings, head MRI, AQP4-Ab status, and average thickness of pRNFL, were not significantly correlated with the final visual outcomes ([Table 3](#tab3){ref-type="table"}).

3.7. Final Diagnosis {#sec3.7}
--------------------

At the last follow-up, there are 11 patients diagnosed with NMOSD, 4 with CRION, 1 with MS-ON, 1 with infectious ON, and 15 with autoimmune ON. None of the elderly group developed NMOSD or MS.

4. Discussion {#sec4}
=============

Only a few cases of ON in middle-aged or elderly patients have been reported to date. In our study, the principal findings in ON patients ≥45 years were predominantly unilateral disease, severe reduction in visual acuity at presentation, and little recovery at 5-year follow-up.

The ONTT reported good recovery of BCVA in younger patients (18--45 years), with 36% having initial BCVA ≤ 20/200 and 8% with final BCVA ≤ 20/200 \[[@B4]\]. Other studies which included ON patients of all ages also reported better outcomes than our observation. A study of 27 native African patients conducted in Nigeria reported initial BCVA ≤ 20/200 in 60% and only 9% at 12-week follow-up \[[@B7]\]. However, the study only included 1 patient who was older than 50 years.

In the first ON study in older patients reported in 1988, outcomes were worse compared to the above two studies, with 61% having initial BCVA ≤ 20/200 and 17% final BCVA ≤ 20/200 \[[@B14]\].

A recent study, which is conducted in Korea, reported that patients \> 50 years recovered well from ON attacks; all affected eyes had final BCVA \> 20/40 within two months \[[@B15]\]. However, the small sample size, eight patients in total, may result in increase of the bias. In our study, we divided patients into two subgroups, one middle-aged group (45--65 years) and one elderly group (age ≥ 65 years). In comparison with the above studies, 64% of the middle-aged group and 100% of the elderly group had initial BCVA \< 20/200 and 43% of the middle-aged group and 88% of the elderly group had final BCVA \< 20/200, showing that visual recovery correlated inversely with age, that is, older patients recovered less vision in this cohort.

The first identified predictor of visual outcomes in this study is initial BCVA. ONTT reported a significant correlation between initial and final BCVA, consistent with our observations \[[@B6]\]. Other predictor in this study is the changes of pRNFL thickness in the temporal. pRNFL thinning manifested within 3 to 6 months after acute ON attack, then remained stable \[[@B16]\]. At 5-year follow-up, we observed particularly thinning in the temporal in patients with final BCVA \< 20/400, compared to patients with final BCVA ≥ 20/400. Similar findings have been previously reported in ON patients by Pro et al. \[[@B17]\].

At 5-year follow-up, there were 11 patients diagnosed with NMOSD, 4 with CRION, and 1 with MS-ON. None of the elderly patients developed NMOSD or MS. Despite severe visual loss, elderly patients were less likely to have a diagnosis of NMOSD or MS. ONTT concluded that the risk of developing to MS is heavily dependent upon the MRI findings at onset \[[@B6]\]. For those patients with a normal brain MRI, a 15-year MS risk was 25%. In contrast, those with one or more MRI lesions consistent with demyelination had a 72% risk, with a higher lesion count conferring an even greater risk \[[@B18]\]. It has also been recognized that the risk of developing to NMOSD is higher in patients of Asian origin \[[@B19]\]. This may be associated with the high detection rate of AQP4-Ab in Asia (32.6%) compared to western countries (5.8%) \[[@B20], [@B21]\].

Myelin oligodendrocyte glycoprotein antibody (MOG-Ab) is also found associating with ON \[[@B22]--[@B24]\]. It was initially reported in a study of paediatric demyelinating disease and further reported in a series of related disorders: NMOSD, acute disseminated encephalomyelitis (ADEM), cortical encephalitis, Hashimoto\'s encephalopathy, epilepsy, LETM, recurrent ON, and MS \[[@B25]--[@B27]\]. However, because this is a retrospective study, MOG antibody test was not available at the time. The strength of our study is that we carefully excluded the diagnosis of NAION in this cohort. NAION constitutes one of the major causes of blindness or seriously impaired vision among the middle-aged and elderly population \[[@B28]\]. Previous study on patients older than 50 years concluded that 6.25 patients per 100000 inhabitants were affected with NAION per year in Beijing \[[@B29]\]. NAION and ON patients share many symptoms and signs \[[@B30]\]. In this study, we did not only exclude patients with the risk factors for NAION, but also used MRI and FFA to further confirm the diagnosis, in order to obtain the uniform sample of the first episode of optic neuritis.

5. Conclusions {#sec5}
==============

In summary, ON in the older population is less likely to develop to NMOSD or MS, especially in elderly patients (≥65 years), even though patients tend to present with more severe visual loss and poor recovery following classic steroid treatment. Further prospective studies are needed to confirm our observations and find an optimal treatment strategy for this population.
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![Peripapillary retinal nerve fibre layer (pRNFL) thickness measured by OCT. Temporal pRNFL was significantly reduced in eyes with BCVA \< 20/400, (*p* \< 0.05).](JOPH2017-3458356.001){#fig1}

###### 

Baseline characteristics of middle-aged and older patients.

  Baseline characteristics           Frequency      Middle-aged group (age \< 65 years)   Elderly group (age ≥ 65 years)   *p* value               
  ---------------------------------- -------------- ------------------------------------- -------------------------------- ----------------------- ----
  Total patients                     76             68                                    8                                ---                     
  Age at onset (years)               Average        55.53 ± 8.29 (45--83)                 53.28 ± 5.05 (45--65)            74.75 ± 4.56 (72--83)   NS
  Gender *n* (%)                     Male           44 (57.9)                             30 (44.1)                        2 (25)                  NS
  Female                             32 (42.1)      38 (55.9)                             6 (75)                                                   
  Laterality, *n* (%)                Unilateral     53 (69.7)                             49 (72.1)                        4 (50)                  NS
  Bilateral                          23 (30.3)      19 (27.9)                             4 (50)                                                   
  Pain, *n* (%)                      Present        25 (53.2)                             22 (50.0)                        3 (100)                 NS
  Absent                             22 (46.8)      22 (50.0)                             0 (0)                                                    
  Initial disc appearance, *n* (%)   Present        30 (40.5)                             29 (50.0)                        1 (87.5)                NS
  Absent                             44 (59.5)      37 (50.0)                             7 (12.5)                                                 
  Autoimmune antibodies, *n* (%)     Normal         43 (67.2)                             38 (67.9.0)                      5 (67.2)                NS
  Abnormal                           21 (21.8)      18 (32.1)                             3 (32.8)                                                 
  AQP4 antibody, *n* (%)             Seropositive   10 (20.4)                             10 (22.2)                        0 (0)                   NS
  Seronegative                       39 (79.6)      35 (77.8)                             4 (100.0)                                                
  CSF study, *n* (%)                 Normal         23 (50.0)                             23 (51.1)                        0 (0)                   NS
  Abnormal                           23 (50.0)      22 (48.9)                             1 (100.0)                                                
  Orbit MRI, *n* (%)                 Normal         9 (17.0)                              7 (14.9)                         2 (33.3)                NS
  Abnormal                           44 (83.0)      40 (85.1)                             4 (66.7)                                                 
  Head MRI, *n* (%)                  Normal         26 (52.0)                             25 (55.6)                        1 (20.0)                NS
  Abnormal                           24 (48.0)      20 (44.4)                             4 (80.0)                                                 
  Relapse rate (N/Y)                 Average        0.46 ± 0.23 (0.14--1)                 0.46 ± 0.23                      0.44 ± 0.18             NS

CSF: cerebrospinal fluid; AQP4-Ab: anti-aquaporin-4 antibody; MRI: magnetic resonance imaging.

###### 

Factors for visual prognosis in middle-aged and elderly patients with optic neuritis.

  Factors                                   Number of patients with final VA \< 20/400   Number of patients with final VA ≥ 20/400   *p* value
  ------------------------- --------------- -------------------------------------------- ------------------------------------------- -----------
  Initial BCVA              \>20/400        3                                            16                                          0.001^∗^
  \<20/400                  35              22                                                                                       
  Sex                       Male            15                                           17                                          NS
  Female                    23              21                                                                                       
  Age                       \<65            31                                           37                                          NS
  ≥65                       7               1                                                                                        
  Laterality                Unilateral      24                                           29                                          NS
  Bilateral                 14              9                                                                                        
  Initial disc appearance   Normal          23                                           21                                          NS
  Swollen                   14              16                                                                                       
  Systemic association      Normal          20                                           23                                          NS
  Abnormal                  10              11                                                                                       
  CSF                       Normal          10                                           12                                          NS
  Abnormal                  13              11                                                                                       
  Serum AQP4-Ab status      Seropositive    7                                            3                                           NS
  Seronegative              17              22                                                                                       
  Orbital MRI               Normal          4                                            5                                           NS
  Abnormal                  22              22                                                                                       
  Brain MRI                 Normal          11                                           15                                          NS
  Abnormal                  13              11                                                                                       
  pRNLF                     Average         64.00 ± 12.91                                68.58 ± 18.70                               NS
  Superior                  69.52 ± 20.72   79.23 ± 32.63                                NS                                          
  Nasal                     59.60 ± 9.39    60.35 ± 10.00                                NS                                          
  Inferior                  72.88 ± 23.53   83.88 ± 30.37                                NS                                          
  Temporary                 50.85 ± 15.81   52.92 ± 10.15                                0.045^∗^                                    

BCVA: best corrected visual acuity; CF: count finger; CSF: cerebrospinal fluid; AQP4-Ab: anti-aquaporin-4 antibody; MRI: magnetic resonance imaging; pRNLF: peripapillary retinal nerve fibre layer, NS: nonsignificant; ^∗^*p* \< 0.05.

###### 

Visual outcomes Of Chinese middle-age and elder patients with optic neuritis.

  Visual outcomes (worse eye at onset if bilateral)   Initial BCVA   Final BCVA                  
  --------------------------------------------------- -------------- ------------- ------------- -------------
  NLP ≤ BCVA \< CF                                    31 (45.6)      8 (100)       16 (23.5)     2 (25.0)
  CF ≤ BCVA \< 20/400                                 18 (26.5)      0             14 (20.6)     5 (62.5)
  20/400 ≤ BCVA \< 20/66                              14 (20.6)      0             17 (25.0)     0
  20/66 ≤ BCVA \< 20/20                               3 (4.4)        0             17 (25.0)     1 (12.5)
  BCVA ≥ 20/20                                        2 (2.9)        0             4 (5.9)       0
  Total                                               68             8             68            8
  Average LogMar BCVA                                 1.94 ± 0.86    2.63 ± 0.30   1.28 ± 0.98   1.72 ± 0.83
  *p* value                                           0.006^∗^       NS                          

NLP: light perception; LP: light perception; BCVA: best corrected visual activity; ^∗^*p* \< 0.05.
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